We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Origenis Receives Grant to Develop New Diagnostic Tools
News

Origenis Receives Grant to Develop New Diagnostic Tools

Origenis Receives Grant to Develop New Diagnostic Tools
News

Origenis Receives Grant to Develop New Diagnostic Tools

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Origenis Receives Grant to Develop New Diagnostic Tools"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

LRRK2 inhibitors are expected to be useful for the treatment of Parkinson’s disease and other neurodegenerative disorders.

The objective of this biomarker program is the development of fluorine labelled, LRRK2 specific, CNS penetrating compounds that will be used to visualize the disease progression in animal Parkinson’s models.

Origenis receives a two-years-grant from the Leading-Edge Cluster program “m4 – Personalized Medicine and Targeted Therapies”.

Advertisement